Clinical Manifestations and Esophageal Complications of GERD

American Journal of the Medical Sciences

Volumn 326, Issue 5, 2003, Pages 279-284

  Spechler, Stuart Jon ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Barrett esophagus; Esophageal neoplasms; Esophageal stricture; Esophagitis; Peptic

Indexed keywords

COLLAGEN; PEPSIN A;

BARRETT ESOPHAGUS; CLINICAL FEATURE; CONFERENCE PAPER; ESOPHAGUS HEMORRHAGE; ESOPHAGUS MUCOSA; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FIBROSIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; METAPLASIA; STOMACH JUICE;

EID: 0242695066     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200311000-00004     Document Type: Conference Paper

References (47)

1. Spechler SJ. A 59 year-old woman with gastroesophageal reflux disease and Barrett esophagus. JAMA 2003;289:466-75.
2. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
3. Richter JE. Dysphagia, odynophagia, heartburn, and other esophageal symptoms. In: Feldman M, Friedman LS, Sleisenger MH, editors. Sleisenger & Fordtran's gastrointestinal and liver disease. Philadelphia: WB Saunders; 2002. p. 93-101.
4. Spechler SJ, Jain SK, Tendler DA, et al. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:1795-800.
5. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-92.
6. Baldi F, Ferrarini F, Longanesi A, et al. Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 1989;34:1890-3.
7. Smith JL, Opekun AR, Larkai E, et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683-9.
8. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001;281:G743-51.
9. Steinbach J, Fass R, Mittal RK. Assessment of relationship between acid reflux and heartburn using receiver operating characteristic curves. Gastroenterol Clin North Am 2002;31(4 Suppl):S45-58.
10. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroe nterol 1999;94:1434-42.
11. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol 2000;30(3 Suppl):S39-41.
12. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-9.
13. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
14. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995;90:206-10.
15. Cappell MS, Sciales C, Biempica L. Esophageal perforation at a Barrett's ulcer. J Clin Gastroenterol 1989;11:663-6.
16. Diehl JT, Thomas L, Bloom MB, et al. Tracheoesophageal fistula associated with Barrett's ulcer: the importance of reflux control. Ann Thorac Surg 1988;45:449-50.
17. Marks RD, Shukla M. Diagnosis and management of peptic esophageal strictures. Gastroenterologist 1996;4:223-37.
18. Ferguson R, Dronfield MW, Atkinson M. Cimetidine in treatment of reflux oesophagitis with peptic stricture. Br Med J 1979;2:472-4.
19. Farup PG, Modalsli B, Tholfsen JK. Long-term treatment with 300 mg ranitidine once daily after dilatation of peptic oesophageal strictures. Scand J Gastroenterol 1992;27:594-8.
20. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994;107:1312-8.
21. Dakkak M, Hoare RC, Maslin SC, et al. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut 1993;34:152-5.
22. Triadafilopoulos G. Nonobstructive dysphagia in reflux esophagitis. Am J Gastroenterol 1989;84:614-8.
23. Spechler SJ. AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999;117:233-54.
24. Spechler SJ. Barrett's esophagus. N Engl J Med 2002;346:836-42.
25. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
26. Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002;16:671-3.
27. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
28. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus. The need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998;93:1033-6.
29. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
30. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
31. Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
32. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
33. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
34. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 2002;97:1319-27.
35. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86.
36. Soni A, Sampliner RE, Sonnenberg A. Screening for highgrade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 2000;95:2086-93.
37. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
38. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360:1587-9.
39. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
40. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
41. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
42. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
43. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
44. Swisher SG, DeFord L, Merriman KW, et al. Effects of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000;119:1126-34.
45. Van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999;94:1153-60.
46. Reid BJ, Blount PL, Feng Z, et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:3089-96.
47. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.